Abstract
Introduction
Insulin resistance is a highly prevalent metabolic condition fraught with
unmet need. Although several diagnostics are in use, not one is ideal; a
standardized, simple tool for measuring IR in clinical practice is needed.
Novel technologies have the potential to create widespread testing for IR in
clinical settings, which would enable early diagnosis and treatment of
prediabetic patients.
Get the Answers You Need to Shape Your Strategy
- Insulin resistance has been tied to many other conditions, including
diabetes, heart attacks, and dyslipidemia. What are the benefi ts of early
insulin resistance diagnosis?
- Several IR tests are used in experimental settings but not widely in
clinical practice. What are the shortcomings of the current tests and what
are clinicians looking for in an IR test?
- Several indexes and tests are used to measure IR, and there is no standard
test used in clinical practice. What are the most common diagnostics used?
Which companies are working toward creating new diagnostics?
- Diagnostic tests that enable earlier detection and therapeutic
intervention for IR may help to delay or prevent the onset of type 2 diabetes
and other diseases. What is the outlook for the current and novel IR
diagnostics and what is their commercial potential?
Scope
- Overview and unmet needs of insulin resistance: defi nition of IR
and metabolic syndrome; unmet need in IR testing; link between IR and other
diseases.
- Epidemiology of insulin resistance: prevalence estimates of IR in
the United States and Europe.
- Current IR diagnostics: Euglycemic hyperinsulinemic clamp,
steady-state plasma glucose, fasting plasma glucose, oral glucose tolerance
test, and others.
- New diagnostics and key players: KineMed' s KineMarkers,
Isotechnika' s Diatest, LipoScience' s NMR LipoProfi le, Entelos' s Metabolism
PhysioLab.
- Outlook and commercial potential: prospects of current and future
diagnostic techniques meeting the unmet need of IR testing.
| 
View Cart
